Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

The present invention provides a compound of Formula I:, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegene...

Full description

Saved in:
Bibliographic Details
Main Authors KIELBASA, William Brian, MERGOTT, Dustin James
Format Patent
LanguageEnglish
Published 23.02.2023
Subjects
Online AccessGet full text

Cover

Loading…